Publication:
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Simple item page
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsHizal, Mutlu; Bilgin, Burak; Paksoy, Nail; Acikgoz, Ozgur; Sezer, Ahmet; Gurbuz, Mustafa; Ak, Naziye; Yucel, Sebnem; Ayhan, Murat; Erol, Cihan; Demirkiran, Aykut; Mandel, Nil Molinas; Shbair, Abdallah; Gokmen, Ivo; Basoglu, Tugba; Paydas, Semra; Demiray, Atike Gokcen; Iriagac, Yakup; Sakalar, Teoman; Zeynelgil, Esra; Tatli, Ali Murat; Bahceci, Aykut; Guven, Deniz Can; Caner, Burcu; Can, Alper; Gulmez, Ahmet; Karakas, Yusuf; Yalcin, Bulent; Demirkazik, Ahmet; Bilici, Ahmet; Aydiner, Adnan; Yumuk, Perran Fulden; Sendur, Mehmet Ali Nahit
dc.date.accessioned2022-03-12T22:59:22Z
dc.date.available2022-03-12T22:59:22Z
dc.description.abstractIntroduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile.
dc.identifier.doi10.1007/s00432-021-03748-7
dc.identifier.eissn1432-1335
dc.identifier.issn0171-5216
dc.identifier.pubmed34331582
dc.identifier.urihttps://hdl.handle.net/11424/237304
dc.identifier.wosWOS:000679766900001
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOsimertinib
dc.subjectNon-small cell lung cancer
dc.subjectEGFR
dc.subjectT790M
dc.subjectSecond line
dc.subjectCHEMOTHERAPY
dc.subjectTHERAPY
dc.subjectPROGRAM
dc.subjectTIME
dc.titleThe real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
dc.typearticle
dspace.entity.typePublication
local.avesis.idffd69354-68f8-4566-8d23-aeea4c28d53f
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages8
oaire.citation.titleJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication.latestForDiscovery4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa

Files

Collections

Research Outputs